(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on long-acting, targeted chronic disease therapies, advanced PEGylation reagents and contract services, with AI, genomics and smart manufacturing reshaping R&D.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "PEGylated Proteins Market Report 2026" has been added to ResearchAndMarkets.com's offering.
PEGylated Proteins Market Projected to Reach $3 Billion by 2030 as Demand for Long-Acting Therapeutics Rises
The global PEGylated proteins market is experiencing rapid expansion as pharmaceutical and biotechnology organizations increase investment in long-acting protein therapeutics, targeted drug delivery and advanced biopharmaceutical production. The market is expected to grow from $1.67 billion in 2025 to $1.9 billion in 2026, representing a compound annual growth rate (CAGR) of 13.7%.
By 2030, the PEGylated proteins market is forecast to reach $3 billion, expanding at a CAGR of 12.1%. Historical market growth has been supported by the need to address the high immunogenicity and limited half-life of unmodified therapeutic proteins. The industry has also benefited from rising awareness of PEGylation's clinical advantages and continued improvements in protein modification technologies and services.
Growth during the forecast period will be driven by expanding research and development in PEGylated therapeutics, increasing demand for long-acting protein drugs and wider adoption of targeted protein therapies. The growing availability of contract PEGylation services, specialized kits and advanced reagents is also expected to support product development and commercial manufacturing.
Technology adoption is reshaping the PEGylated proteins industry. Key market trends include the use of artificial intelligence in protein engineering and PEGylation processes, genomics-informed therapeutic development and cloud-based research data management. Biopharmaceutical manufacturers are also implementing smart manufacturing systems and Internet of Things-enabled monitoring to improve production visibility, process consistency and operational efficiency.
The rising prevalence of lifestyle-related diseases is a major factor supporting PEGylated proteins market growth. Conditions associated with poor dietary patterns, physical inactivity, smoking and elevated stress levels are becoming increasingly common. PEGylated therapeutics can improve the effectiveness, duration and delivery of treatments used for cardiovascular disease, diabetes and certain cancers. According to the UK Office for Health Improvement and Disparities, an estimated 64% of adults aged 18 and older in England were classified as overweight or living with obesity during 2022-2023, highlighting the growing burden of preventable health conditions.
The increasing prevalence of chronic diseases is also strengthening demand for PEGylated protein therapies. Aging populations, sedentary lifestyles, unhealthy diets and environmental factors are contributing to higher rates of cardiovascular disease, diabetes, chronic respiratory disorders and cancer. PEGylated proteins can enhance therapeutic stability and efficacy while reducing treatment frequency, potentially improving adherence and patient outcomes.
In June 2025, the World Health Organization reported that noncommunicable diseases remained the leading cause of death and disability worldwide, including across the WHO European Region. The organization noted that one in five men and one in 10 women die before age 70 from conditions such as cardiovascular diseases, cancers, chronic respiratory diseases and diabetes. This sustained disease burden is expected to increase demand for innovative biologic medicines and longer-acting treatment options.
Product innovation remains an important competitive focus within the PEGylated proteins market. Manufacturers and specialist suppliers are advancing PEGylation reagents designed to support biomedical research and targeted drug delivery. In May 2023, Creative Enzymes introduced DSPE-PEG-Maleimide for targeted drug delivery applications. The linear heterobifunctional reagent combines DSPE phospholipids with maleimide groups and supports the preparation of PEGylated liposomes or micelles. Its thiol- and cysteine-reactive characteristics make it applicable to targeted delivery system development.
North America was the largest region in the PEGylated proteins market in 2025. The global market coverage includes Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.
Markets Covered:
1) By Product: Consumable And Services; PEGylation Kits And Reagents; Monofunctional Linear PEGs; Bifunctional PEGs; Other Products
2) By Protein Type: Colony Stimulating Factors; Interferons; Erythropoietin; Recombinant Factor VII; Other Protein Types
3) By Application: Cancer Treatment; Hepatitis; Chronic Kidney Diseases; Hemophilia; Multiple Sclerosis; Gastrointestinal Disorders; Other Applications
4) By End User: Pharmaceuticals; Biotechnology Companies; Contract Research Organizations; Academic Research Institutes
Subsegments:
1) By Consumable And Services: Consumables; Services
2) By PEGylation Kits And Reagents: PEGylation Kits; Reagents
3) By Monofunctional Linear PEGs: Monofunctional PEGs For Protein Modification
4) By Bifunctional PEGs: Bifunctional PEGs For Protein Modification
5) By Other Products: Conjugates; PEGylated Drugs And Therapeutics
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment